1,122 reports of this reaction
1.8% of all ANAKINRA reports
#9 most reported adverse reaction
PYREXIA is the #9 most commonly reported adverse reaction for ANAKINRA, manufactured by Swedish Orphan Biovitrum AB (publ). There are 1,122 FDA adverse event reports linking ANAKINRA to PYREXIA. This represents approximately 1.8% of all 60,861 adverse event reports for this drug.
Patients taking ANAKINRA who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for ANAKINRA, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for ANAKINRA:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,122 FDA reports for ANAKINRA. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 1.8% of all adverse event reports for ANAKINRA, making it a notable side effect.
If you experience pyrexia while taking ANAKINRA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.